Redx Pharma Financial Statements
Redx Pharma Financial Overview
Redx Pharma's market cap is currently ―. The company's EPS TTM is p-0.07; its P/E ratio is -11.09; Redx Pharma is scheduled to report earnings on January 26, 2023, and the estimated EPS forecast is p―. See an overview of income statement, balance sheet, and cash flow financials.
| Sep 21 | Sep 20 | Sep 19 | Sep 18 | Sep 17 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | p 10.04M | p 5.68M | p 3.13M | p 129.00K | p 30.47M |
| Gross Profit | p ― | p 5.68M | p 2.78M | p 129.00K | p ― |
| EBIT | p -19.73M | p -8.19M | p -6.23M | p -10.14M | p 2.01M |
| EBITDA | p -19.10M | p -7.53M | p -6.14M | p -9.98M | p 2.34M |
| Net Income Common Stockholders | p -21.58M | p -9.21M | p -4.32M | p -8.85M | p 1.53M |
| Balance Sheet | |||||
| Cash, Cash Equivalents and Short-Term Investments | p 3.20M | p 5.76M | p 6.47M | p 23.81M | p 27.51M |
| Total Assets | p 39.55M | p 32.93M | p 6.36M | p 10.32M | p 27.69M |
| Total Debt | p 0.00 | p 17.29M | p 20.47M | p 575.00K | p 2.00M |
| Net Debt | p -3.20M | p 11.53M | p 14.00M | p -23.23M | p -25.51M |
| Total Liabilities | p 26.41M | p 30.90M | p 4.87M | p 4.55M | p 13.36M |
| Stockholders Equity | p 1.49M | p 1.72M | p 2.03M | p 5.76M | p 13.13M |
| Cash Flow | |||||
| Free Cash Flow | p -22.13M | p 336.00K | p -4.70M | p -17.31M | p 13.94M |
| Operating Cash Flow | p -21.38M | p 395.00K | p -4.67M | p -17.18M | p 14.10M |
| Investing Cash Flow | p -754.00K | p -55.00K | p 32.00K | p -109.00K | p -30.00K |
| Financing Cash Flow | p 24.14M | p 23.47M | p 1.87M | p -49.00K | p 3.98M |